rethinkTHC Search
Menu
Study breakdown

Cannabinoids Show Anticancer Properties in Lab and Animal Studies, But Clinical Evidence Is Limited

ReviewModerate evidence
The takeaway

Preclinical studies show cannabinoids can inhibit cancer cell proliferation, stimulate cell death, and potentially block tumor blood supply and metastasis, but human clinical trial data remains sparse.

Oncology researchers, cancer patients interested in cannabis, medical cannabis advocates.

Cannabinoids showed anticancer effects through proliferation inhibition, autophagy and apoptosis stimulation, and anti-angiogenesis, but some studies found cancer cell stimulation.

What the researchers found

Cannabinoids exhibit anticancer properties through multiple mechanisms: inhibiting cell proliferation, stimulating autophagy and apoptosis, and potentially inhibiting angiogenesis and metastasis. However, the review also discusses cases where cannabinoids stimulated cancer cell proliferation, and notes the complex role of the endocannabinoid system in cancer development.

Why it matters

While cannabinoids are currently approved only for palliative cancer care (pain and nausea), growing preclinical evidence suggests they may have direct anticancer properties. Understanding both the promise and complexity is essential for responsible research translation.

The numbers in context

Multiple signaling pathways identified, including those controlling cell proliferation and survival. Both in vitro and in vivo evidence reviewed across multiple cancer types.

How the study worked

Review of in vitro and in vivo preclinical evidence for cannabinoid anticancer activity, molecular mechanisms, and currently ongoing clinical trials.

What this study cannot tell us

Most evidence is preclinical. In vitro conditions differ significantly from human tumors. Dosing in animal studies may not translate to humans. Limited clinical trial data available at time of review.

How to read the evidence

Moderate - comprehensive review of substantial preclinical evidence, but clinical trial data was sparse at time of publication.

When this study was published

Published in 2018. Several clinical trials evaluating cannabinoids as anticancer agents have since progressed.

The bigger picture

The review highlights that cannabinoid-cancer interactions are not uniformly anti-tumor. Some evidence suggests cannabinoids can stimulate cancer cell proliferation under certain conditions, and the endocannabinoid system's role in carcinogenesis itself is not fully understood.

Questions still open

  • Under what conditions might cannabinoids promote rather than inhibit cancer growth? Which cancer types are most responsive to cannabinoid treatment? Could cannabinoids enhance the effectiveness of conventional chemotherapy?

Common questions

Can cannabis cure cancer?
Preclinical studies (lab and animal) show cannabinoids can kill cancer cells and inhibit tumor growth through multiple mechanisms. However, human clinical trial evidence is still limited, and some studies have found cannabinoids can stimulate cancer cell growth under certain conditions.
How might cannabinoids fight cancer?
Lab studies show cannabinoids can inhibit cancer cell proliferation, trigger programmed cell death (apoptosis and autophagy), and potentially block the formation of blood vessels that feed tumors (angiogenesis) and cancer spread (metastasis).

Read the original research

The current state and future perspectives of cannabinoids in cancer biology.

Cancer medicine, 7(3), 765-775

Citation

Śledziński, Paweł; Zeyland, Joanna; Słomski, Ryszard; Nowak, Agnieszka. (2018). The current state and future perspectives of cannabinoids in cancer biology.. Cancer medicine, 7(3), 765-775. https://doi.org/10.1002/cam4.1312

Explore the wider topic